Article ID Journal Published Year Pages File Type
8680548 Alzheimer's & Dementia: Translational Research & Clinical Interventions 2017 5 Pages PDF
Abstract
Assuming the improvement at first follow-up observed in this trial represents PEs, the rate of change from the second assessment forward is a more accurate representation of symptom progression in this population and is the appropriate reference point for describing treatment effects characterized as percent slowing of symptom progression; failure to accommodate this leads to an oversized clinical trial. We conclude that PEs are an important potential consideration when planning future trials.
Related Topics
Life Sciences Neuroscience Neurology
Authors
, , , , , ,